Pharmaceutical Executive October 4, 2024
Mike Hollan

Dr. Wagner discusses her work with the Bill and Melinda Gates Medical Research Institute.

An unfortunate reality of the pharmaceutical industry is that profit is often more of a motivator for drug development than helping patients. As head of corporate strategy and market access at the Bill Melinda Gates Medical Research Institute, Dr. Claire Wagner works to get medications produced or developed that are sorely needed but may not fit into the typical profit-structure of a commercial pharmaceutical company.

Pharmaceutical Executive: What are the largest global health concerns for which investment incentives are limited?
Dr. Claire Wagner: The COVID-19 pandemic showed some critical vulnerabilities in health systems across high income countries with strong economies, regardless of income levels. At the Gates...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Interview / Q&A, Pharma, Pharma / Biotech, Trends
What might a Trump administration mean for the Biosecure Act?
Q&A: Reducing Mental Health Stigma Starts in Pharmacies
Flagship, Pfizer alliance yields two more startup deals
Payment Disrupters and Opportunities: Key Trends That Impacted Pharmacy in 2024
Wondr Health Expands Weight Loss Program with Support for GLP-1 Users

Share This Article